key: cord-0254143-mgh9vrsm authors: Lopez-Jaime, F. J.; Martin-Tellez, S.; Doblas-Marquez, A.; Marquez-Gomez, I.; Reguera-Iglesias, J. M.; Munoz-Perez, M. I.; Fernandez-Bello, I.; Montano, A. title: CLOT STIFFNESS MEASURED BY SEER SONORHEOMETRY AS A MARKER OF POOR PROGNOSIS IN HOSPITALIZED COVID-19 PATIENTS date: 2021-07-16 journal: nan DOI: 10.1101/2021.07.13.21260256 sha: 11f65796af58acaad5ba1678ba46267c9b28fe71 doc_id: 254143 cord_uid: mgh9vrsm Background: High incidence of life-threatening thrombotic complications is observed in severely ill COVID-19 patients. D-dimer may help evaluate disease severity and predict outcomes at hospital admission. However, its non-specificity and long analysis times strongly constrain its clinical value. Viscoelastic tests (VET) are widely available rapid point-of-care devices that have been shown to detect a hypercoagulable state (increased clot stiffness and fibrinolysis shutdown) as major contributors of the thrombotic complication in COVID-19. Nevertheless, based on the data obtained so far, definitive conclusions have not been drawn. Objectives: We aim to evaluate the association between VET parameters, standard coagulation tests and inflammation markers assessed in COVID-19 patients at hospital admission with disease severity and outcomes. Patients/Methods: A total of 69 COVID-19 patients requiring hospitalization were included in the study. The pro-inflammatory and pro-thrombotic state was analyzed by a panel of inflammation markers (IL-6, CRP, LDH, ferritin), routine coagulation tests (PT, aPTT, platelet count, fibrinogen, D-dimer) and a SEER sonorheometry VET profile (Quantra System). Results: Inflammatory markers IL-6, CRP, LDH and ferritin were elevated in a high percentage of patients (73.6%, 89.2%, 57.1% and 52.4%), as were coagulation-related parameters such as fibrinogen (81.4%) and D-dimer levels (66.2%). Quantra analysis revealed increased clot stiffness (CS) in 34.8%, particularly due to increased fibrinogen contribution (FCS) in 63.7%. Increased clot stability to lysis (CSL) was observed in 32.4%. Age > 65 years, elevated values of fibrinogen, D-dimer, LDH, increased clot stiffness and resistance to clot lysis were significantly associated with worsening disease. The Quantra FCS parameter showed a particularly high prognostic value in distinguishing patients with severe symptomatology. Conclusion: The global study of hemostasis by the whole blood point-of-care Quantra VET system may be a powerful tool for identifying poor prognosis in COVID-19 patients at hospital admission. In particular, FCS measured by Quantra could be established as a plausible prognostic marker to aid the clinical management of COVID-19 patients. At the moment of writing this article, coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already killed more than 3 million people worldwide [1] . The development of an extreme inflammatory response and prothrombotic state is 55 associated with poor prognosis and remains the major cause of the high morbidity and mortality rate 56 associated with this condition [2, 3] . Citrated, EDTA and non-anticoagulated blood samples were drawn on hospital admission and after confirmation of SARS-CoV-2 infection. Quantra ® Hemostasis Analyzer (HemoSonics, Charlottesville, (CSL) . Details of Quantra QPlus and QStat cartridges have been described previously [17, 18] . Complete The statistical software "SPSS statistics" (IBM) was used for the analysis. Comparison for qualitative 117 (Chi-square test or Fisher's Exact Test) and quantitative differences (Mann-Whitney U test) were applied. Relationship between parameters at admission and disease severity or adverse events was assessed by ROC 119 curve analysis. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. Table 3 shows the proportion of elevated levels of all assessed parameters, defined as the proportion 148 above the upper limit of normal (ULN), in the total cohort as well as in patients who did not experience an 149 adverse event and those who did. Inflammation and tissue damage markers were elevated in at least half of 150 the patients: IL-6 in 73.6%, CRP in 89.2%, LDH in 57.1% and ferritin in 52.4%. Regarding coagulation 151 parameters, shortened PT and aPTT clot times, i.e., below the lower limit of normal (LLN), were only 152 observed in 0% and 14.5%, respectively. An elevated platelet count was only present in 8.7% of all patients. In contrast, fibrinogen and D-dimer were elevated in 81.4% and 66.2%, respectively. On the Quantra 154 system, shortened CT and CTH clot times (below LLN) were only observed in 8.7% and 14.7%, 155 respectively. Total clot stiffness (CS) was elevated in 34.8%, with an elevated PCS and FCS in 27.6% and 156 63.7%, respectively. A CSL value of 100% (suggesting absence of fibrinolysis) was observed in 32.4%. Table 3 . Markers of inflammation and tissue damage, coagulation and Quantra parameters: proportion 159 above upper limit of normal (ULN) or below the lower limit of normal (LLN) in COVID-19 patients with no 160 adverse events versus those with adverse events. In the case of PT, aPTT, CT and CTH, the percentage of patients 161 with times below the lower limit of normal values was considered. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. Only, LDH, D-dimer, the Quantra clot stiffness parameters (CS and FCS) and resistance to lysis ( . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260256 doi: medRxiv preprint We present the results of a pilot study in which we evaluated the use of global viscoelastic hemostatic were analyzed using standard laboratory tests for coagulation, inflammatory and tissue damage markers Regarding coagulation parameters, COVID-19 patients showed elevated levels of fibrinogen and D-226 dimer, the latter being mostly observed in patients who experienced an adverse event during admission. These results are also in agreement with those reported in the literature, which propose these factors as 228 probably responsible for the thrombotic events that have been observed in COVID-19 patients [3, 4] . VET analysis has also been proposed as a powerful tool for the study of the global hemostatic status One of the limitations of our study is, however, that patients were analyzed only at the time of . The results of our study, which found that FCS has a higher predictive 269 value for an adverse event than D-dimer, indicate that FCS may also be an important parameter to monitor, 270 especially in COVID-19 patients with elevated FCS at hospital admission. In this study we also observed 271 that both elevated FCS and D-dimer were significantly more strongly associated with patients with a worse 272 prognosis, suggesting the joint use of both parameters as a predictor of risk. In summary, we can conclude from this study that the use of the sonorheometry VET technique allows 274 a global analysis of the hemostatic status of COVID-19 patients in a rapid and efficient way, including clot 275 stiffness parameters (CS, PCS, FCS, CSL) that are not routinely measured by standard laboratory tests. The implementation of this technique would allow for a more accurate diagnosis of patients on admission, 277 helping in patient triage. By using this technique, we were able to detect that COVID-19 patients with 278 higher clot stiffness showed a worse prognosis, especially due to the higher contribution of fibrinogen. the Quantra QStat System in adult trauma patients. Trauma Surg. Acute Care Open 2020, 5, e000581, doi:10.1136/tsaco-2020-000581. World Health Organization WHO Coronavirus (COVID-19) Dashboard Available online: 3 Abnormal coagulation parameters are associated with poor 14 The procoagulant pattern of patients with COVID-19 acute respiratory 340 distress syndrome Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy World Health Organization COVID-19 Clinical management: living guidance Available online Comparison of Quantra System The poor 359 prognosis and influencing factors of high D-dimer levels for COVID-19 patients COVID-19 and the cardiovascular 363 system: implications for risk assessment, diagnosis, and treatment options Lactate dehydrogenase, COVID-19 and mortality The Role of TEG Analysis in Patients with A Comparative Study of SEER Sonorheometry Versus Standard Coagulation Tests, Rotational Thromboelastometry, and Multiple Electrode 378 Aggregometry in Cardiac Surgery The role of rotational thromboelastometry during the 388 COVID-19 pandemic: a narrative review Table 2 , patients with adverse events showed significantly higher values of CRP, LDH, As expected, platelet count and fibrinogen levels correlated positively with PCS and FCS values,